Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences

BACKGROUND: Adjuvant chemotherapy (ACT) is considered for high‐risk patients in stage IB lung adenocarcinoma (LUAD). However, these risk factors are recognized as negative prognostic factors, not as predictors of ACT efficacy. This study aimed to analyze the efficacy of ACT in stage IB patients by r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fei, Chen, Heng‐chi, Xu, Haiyan, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Ying, Jianming, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663680/
https://www.ncbi.nlm.nih.gov/pubmed/36104006
http://dx.doi.org/10.1111/1759-7714.14659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663680/
https://www.ncbi.nlm.nih.gov/pubmed/36104006
http://dx.doi.org/10.1111/1759-7714.14659

Ejemplares similares